Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of JNJ-101556143 in metastatic androgen pathway modulation-resistant prostate cancer
CTR20263367Phase 2Active
- Sponsor
- Johnson & Johnson
- Start
- Oct 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HLD-0915 in prostate cancer (PCa), sponsored by Johnson & Johnson. Primary endpoint: Objective response rate. Started Oct 2026; status: active.
02
Drugs
HLD-0915
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20263367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263367.